The tweet was deleted by the author.
But we saved everything 🙂.
Patrick Soon-Shiong, a prominent healthcare innovator, advocates for a shift in cancer treatment paradigms.
He proposes the use of chemotherapy and radiation not just as traditional cancer therapies but as ''immunogenic modulators'' administered in metronomic doses—low and regularly spaced—aiming to harness the body's own immune system in the fight against cancer. ''This is the new paradigm,'' Soon-Shiong asserts, emphasizing that while established standards of care remain relevant, there is room for innovation and adaptation to improve outcomes.
By incorporating reduced doses, the approach seeks to minimize the harmful side effects often associated with conventional treatments. Chemo and radiation, when applied strategically, could play crucial roles in reinforcing or directing the immune response against cancer cells.
This notion, highlighting a shift towards more personalized and less invasive treatment options, aligns with emerging trends in oncology that focus on enhancing quality of life and expanding therapeutic potential.
Soon-Shiong's pursuit of more targeted therapies is emblematic of broader advancements in the field, as illustrated by the recent lung cancer trial data indicating that PDL1 levels do not affect NK cells in pivotal clinical findings. His strategic integration of agents such as Anktiva with Pluvicto for prostate cancer, detailed in his combined modality approach, further exemplifies a commitment to innovative frameworks designed to optimize patient outcomes through tailored treatment regimens.